Business Wire

PM-MIKATI-MEDIA-OFFICE

5.10.2021 12:50:14 CEST | Business Wire | Press release

Share
Lebanon’s PM Mikati Media Office Take on "Pandora Papers"

The Media Office of Lebanon’s Prime Minister Najib Mikati has issued the following statement:

In the context of the recently revealed “Pandora Papers” , it would be important to emphasize the fact that the origin of the wealth of Lebano n’s Prime Minister Najib Mikati is derived from over 20 years of sustained work in the telecom sector, that culminated in 2005, with the listing of the telecom company – (that the Mikati family used to own) – on the main board of the London Stock Exchange ; and its subsequent merger with the Johannesburg-based telecom leader MTN . Therefore, the source of wealth of the Mikati family had been well-scrutinized by the concerned bodies and entities that were piloting the Initial Public Offering (IPO) - thus certifying that the same source of wealth was well-documented, legal, legitimate and audited; and that it derived from the family business’ global activities that preceded the entry of Najib Mikati into politics in Lebanon.

The Monaco property, among other assets around the world, specifically mentioned in the “Papers”, is not the only property owned via a corporate entity. Most family assets and properties fall under the same corporate principle of management and good governance. It is a common and lawful business practice that, in case many family members share the same assets, to organize the ownership via legal entities that offer flexibility as well as corporate, financial and fiscal advantages.

In addition, all the assets and properties belonging to PM Najib Mikati have been duly disclosed to the Constitutional Council in Lebanon, as per the prevailing laws, rules and regulations, since he entered politics.

It is worth highlighting that not all people mentioned in the “Pandora Papers” are necessarily accused of wrongdoings. Also, not all fortunes amassed ought to have necessarily happened at the expense of the common good and needy people.

Regrettably, the underlying logic behind the “Papers” drifted toward transforming most, if not all, of those mentioned into “suspicious” individuals &/or companies, by the mere fact of being listed in there - a logic that goes against the free-market business practices and good governance, in liberal economies, principles that the Mikati family defends.

Since its inception, M1 Group (the Mikati family business) – and all of its subsidiaries around the world – have upheld a separation between public and private. They continue to be fully compliant with global standards; retain world-class auditors; and operate in multiple jurisdictions.

The group respects the right of board members &/or senior executives to run for or hold public office. However, politics &/or public office holders do not influence the group’s guiding principles and business operations; and vice-versa.

At all times, PM Mikati and M1 Group respect the rule of law and abide by it everywhere. All rights reserved.

-Ends-

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye